Answers are grounded in this paper and cite their sources.
Patent demonstrates pyridine derivatives inhibiting CDK2 and CDK4 for cancer treatment, suggesting therapeutic potential.
High Resolution Image Download MS PowerPoint Slide This patent demonstrates a class of compounds that selectively inhibit cyclin-dependent kinases such as cyclin-dependent kinase 2 (CDK2) and cyclin-dependent kinase 4 (CDK4), which are key regulators of the cell cycle implicated in cancer. These compounds and their pharmaceutically acceptable salts are intended for the treatment of conditions, diseases, and disorders mediated by CDK2 and/or CDK4.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: